Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Aprea Therapeutics Inc (APRE)

NASDAQ
Currency in USD
Disclaimer
5.385
+0.225(+4.36%)
Real-time Data

APRE Comments

what happened here?
??
this could be the end!
w
'The emerging data for the combination of eprenetapopt and pembrolizumab in these difficult-to-treat patients is very encouraging,” said Dr. Haeseong Park of Washington University in St. Louis. “Particularly promising are tumor reductions in lung cancer patients who previously received I/O therapy, and the complete remission in a bladder cancer patient with prior chemotherapy exposure, which is rare. In addition, the clinical experience to-date suggests the combination is well-tolerated with adverse events readily managed with standard of care measures. The other investigators and I look forward to maturation of the data from this clinical trial as we seek to enroll and treat additional patients with this novel combination.'
Thanks, do you have any other interesting stock to buy ? look at the premarket.. hope it keeps like this tomorrow opening session
Kinross Gold Corp (KGC) , gold is extremely cheap in a must-have resource at all levels: geopolitical, industrial, coin backing, etc, etc
only +5% in premarket...
https://ir.aprea.com/static-files/47be1f37-ac5f-4302-8ce1-7ad5d2c88839
It was today ~~ Date and Time: Monday, September 20, 2021; 17:35 – 17:40 CEST (11:35 – 11:40am EDT). At this moment APREA have not yet issued the content of the report, but already been. It must be a good report because not fallen too much
I got it: Conclusions • Combination of eprenetapopt + pembrolizumab was safe and well-tolerated as evidenced by • Absence DLTs in the safety cohort • All grade AEs which were manageable with standard of care measures • 1 patient discontinued eprenetapopt due to AEs • Preliminary efficacy signal of disease reduction in 2 of 20 patients with NCSLC previously treated with IO therapy and 1/3 patients with IO-naïve bladder/urothelial cancer who achieved CR • Exploratory studies involving analyses of myeloid cells for inflammatory markers and immunosuppressive phenotype, and T cell phenotyping for exhaustion markers, are ongoing • The trial continues to enroll and treat patients
ok I got 300 shares of this... bought at 4.98 based on a random comment from below. Trusting internet people... that's risky gambling
maybe the +100% on a good day, today was terrible, but if u BUY 4,98 and sold about 5,5X it's a good profit in a very red day
no way look the premarket now... will it hold until tomorrow ?
who knows! what a joke! pre today was at sometime like +20% rude manipulation
Why is it up 20% after market?
not even in their website they announce any event
ok you know what ? I bought some shares... let's see tomorrow if you were right. this is crazy, trusting somebody on the internet, lol
sorry, just copy and paste the text I wrote in the night yesterday, so it's today, see the SEC filling
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2021 from September 16 – 21, 2021.
Great recovery today
Gang, I see bullish reversal happening today should be up day tomorrow.
APRE price targets range from a high of $5.2to a $4.6 in the next 2 weeks.So buy investors buy!
Support $4.20 resistance $5.05
I am long this baby at $4.26
We are in Elliott Wave 2. Bullish momentum to enter.
Every positive announcement is being used to exit. Samething happened on 21st July. There are no upcoming events either. But looking less risky - will enter with SL of 3.75
Dont worry news in July soon is going up 👍🏽👍🏽
I think it's breaking $5 soon
very good United states woold policy and G7💋💋💋💋💋👍👍👍👍👍👍👍👍💲💲💲💲☑️☑️☑️☑️☑️🇺🇸🇺🇸🇺🇸🇺🇸 I love you USA 💋💋💋💋🇪🇹🇪🇹🇪🇹 my name Moaz nezif from Ethiopia +251927812541 money Tarencfer 💲100 0000 +251927812541pone naber sendng
we are currently in wave C of Elliott wave. Support at $4.77 and resistance $5.95
Sold Apr 21 $5 puts $.50 for a total gain of $1,250 let's see if they expire worthless?
back to 20-40 range?
Kinda hope so !!!
 still long?
This should return to mid teens soon
I am afraid, I think they will take it below $5.
just a $h it
company sure did *****all there investors...only people that came out on top was the company and there lavish lifestyle there living
this will go back up to $10 within the next couple months don't panic. The tests still showed positive results, just not considered statistically significant.
Oh my what happen? almost bankrupt
 yes, I bought more shares at 5.52 (average = 8.03)
It wasn't good news but wasn't an end either. Think this will rally back to mid teens in the near future.
what happened
results of phase 3
when are the results coming out on there phase 3 trials
must be worst result
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.